Cachexia, Non-small Cell Lung Cancer
Conditions
Keywords
Cachexia, Non-Small Cell Lung cancer, Anorexia, Malnutrition
Brief summary
The purpose of this study is to assess the frequency of cachexia and the management of cachexia and associated symptoms in a patient population with non-small cell lung cancer (NSCLC).
Detailed description
This is a cross-sectional, non-interventional, European (France and Belgium), multicentric prevalence study, conducted on a representative population of 500 patients with NSCLC, to assess the frequency and the management of cachexia and associated symptoms. The study will be conducted in accordance with the professional code of ethics and the good epidemiological practices guidelines developed by the ADELF (the Association of French-Speaking Epidemiologists) and in accordance with the STROBE recommendations for the drafting of reports and publications related to the study. The information will be collected during a single visit to the oncologist/lung specialist as part of the usual patient management of his/her lung cancer. The physician will explain the purpose of the study to the patient with an information form specific to the study and will inform him/her of the option to refuse or withdraw from participation. The patient information form in France or a specific consent form in Belgium will be signed by the patient and a copy will be given to him/her (the original will be kept by the physician). This study does not require any additional specific data. Data will come from the medical file and from the routine disease management. Furthermore, the following self-completion questionnaires will be proposed to patients: Visual analogue scale for dietary intake (dietary intake VAS), assessment of the concerns associated with the anorexia/cachexia (Anorexia-Cachexia module of the Functional Assessment of Anorexia/Cachexia Therapy \[FAACT\] questionnaire), quality of life (EORTC QLQ-C30), and assessment of physical activity (IPAQ, International Physical Activity Questionnaire). Abdominal CT-scan, if available, will be collected for assessment of skeletal muscle mass index at L3.
Interventions
None listed
Sponsors
French College of General Hospital Pneumologists (CPHG)
French-Speaking Association of Supportive Care in Cancer (AFSOS)
ITEC Services
Chugai Pharma France
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient 18 years of age and older * Patient with NSCLC * Patient who has been informed of the study and who has signed a patient information leaflet for France or an informed consent for Belgium * Patient able to complete a self-assessment questionnaire
Exclusion criteria
* Patient unable to consent and/or unable to sign the patient information form in France or an informed consent in Belgium * Patient with a complete resection of an early stage NSCLC * History of head and neck cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Cachexia According to Modified Fearon Criteria | Day1 | Percentage of NSCLC patients with a cachexia according to Fearon criteria modified for the stages of pre-cachexia and refractory cachexia in order to classify all the featured cases without ambiguity. A patient was considered to have cachexia if he/she had: * Weight loss \>5% in the last 6 months prior to inclusion or * BMI \<20 kg/m² and weight loss between 2 and 5% in the 6 months prior to inclusion or * Weight loss \>2% and sarcopenia (as evaluated by the muscle mass index at L3) if available. If data were not available regarding possible sarcopenia, the presence of cachexia was assigned based on the 2 above conditions. In the 3 cases defined above, patient should not have entered the refractory cachexia stage, which was defined as: ECOG performance score of 3 or 4 and a low survival expectancy as defined by Martin et al. (J Clin Oncol 2015) (BMI \<20 kg/m² and weight loss ≥ 6%) or (20 ≤ BMI ≤ 21.9 kg/m² and weight loss ≥ 11%) or (22 kg/m² ≤ BMI and weight loss ≥ 15%). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of the Different Stages of Cachexia in the General NSCLC Population | Day 1 | Percentage of the different stages of cachexia at inclusion. The different stages of cachexia used the following classification: * No Cachexia: 1) no weight loss (WL\<2%) or 2) weight gain AND no anorexia AND no sarcopenia * The pre-cachexia stage : 1) 2% ≤ weight loss ≤ 5% AND BMI ≥ 20 and/or 2) anorexia (according to question 13 of the quality of life questionnaire QLQ-C30) and/or 3) weight loss \< 2% AND sarcopenia * Cachexia: 1) Weight loss \> 5% OR 2) weight loss between 2 and 5% AND BMI \< 20 kg/m² OR 3) weight loss \> 2% AND sarcopenia. In all cases, patient should not have entered the refractory cachexia stage * Refractory cachexia: ECOG 3 or 4 AND low survival expectancy \[BMI \< 20kg/m² and weight loss ≥ 6%\] OR \[20 ≤ BMI ≤ 21,9 kg/m² and weight loss ≥ 11%\] OR \[22 kg/m² ≤ BMI and weight loss ≥ 15%\] |
| Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Day 1 | Percentage of the different stages of cachexia at inclusion according to the NSCLC stage |
| Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Day 1 | Percentage of the different stages of cachexia according to the NSCLC histology |
| Frequency of Sarcopenia in the General NSCLC Patients With Cachexia | Day 1 | Percentage of patients with sarcopenia in the general NSCLC patients with cachexia |
| Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia | Day 1 | Percentage of patient with sarcopenia and no clinical significant weight loss (sarcopenia and WL\< 2%) in the general NSCLC patients with pre-cachexia: |
| Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Day 1 | Percentage of the different stages of cachexia according to the molecular abnormalities associated with NSCLC: * EGRF, ALK, ROS1, BRAF or HER2 * K-RAS * No mutation |
| Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Day 1 | Stage of cachexia at inclusion according to the type of treatments received (surgery, radiotherapy, chemotherapy, targeted therapies). |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Day 1 | • Nutritional state according to the different stages of cachexia The variables used will be: serum albumin levels, serum pre-albumin levels, BMI and weight. |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Day 1 | Blood glucose abnormalities according to the different stages of cachexia at inclusion |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale | Day 1 | Dietary Intake Visual Analog Scale (Dietary intake VAS): The question Could you indicate the amount you currently eat, placing a vertical mark on the line between nothing at all and as usual? . Depending on the location of the patient mark on the scale, a score of between 0 (nothing at all) and 10 (as usual) will be allocated. |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT | Day 1 | Score of the 12-question AC/S module (Anorexia-Cachexia module) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire assessing anorexia and cachexia: the AC/S module of the FAACT questionnaire consists of 12 questions to assess over the last 7 days quality of life, related to anorexia or cachexia. The score ranges between 0 and 48, the higher the score, the higher the quality of life. |
| Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Day 1 | NSCLC patients. 84 patients with missing data |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP | Day 1 | CRP level |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen | Day 1 | fibrinogen level |
| Description of the Quality of Life Associated With the Different Stages of Cachexia. | Day 1 | Quality of life has been analysed using scores from the functional scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 items (EORTC QLQ-C30 questionnaire): score ranging from 0 (malfunction) to 100 (healthy level of functioning) for the following parameters : physical, role, cognitive, emotional and social scales |
| Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Day 1 | Three levels of physical activity are defined: 1. \- Low * No activity is reported OR * An activity is reported but does not reach moderate or high levels. 2. \- Moderate Corresponds to one of the following 3 criteria: * 3 or more days of intense activity lasting at least 20 min per day OR * 5 or more days of moderate intensity activity and / or walking for at least 30 min per day OR * 5 or more days of activity combining walking, activities of moderate or high intensity, thus achieving at least 600 MET-minutes / week 3. \- High Corresponds to one of the following 2 criteria: * Intense activity at least 3 days a week and at least 1500 MET-minutes / week OR * 7 or more days of activity combining walking, moderate and high intensity activities, achieving at least 3000 MET-minutes / week |
| Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms | Day 1 | Pharmacological treatment of cachexia or associated symptoms: Yes / No |
| Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms | Day 1 | Non-pharmacological treatment of cachexia or associated symptoms: Y/N |
| Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments | Day 1 | Treatments with systemic corticosteroids, anti-inflammatory drugs, Omega 3 fatty acids: Yes/No |
| Number of Participants With Diabetes Treatments | Day 1 | Diabetes treatments : Yes/No |
| Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia | Day 1 | * Proportion of patients with cachexia according to the subjective assessment of the clinician * Proportion of patients with cachexia according to the Fearon criteria |
| Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia | Day 1 | * Proportion of patients with anorexia according to the subjective assessment of the clinician * Proportion of patients with anorexia according to the Ingesta VAS * Proportion of patients with anorexia according to the AC/S-FAACT module score * Proportion of patients with anorexia according to question 13 of the QLQ-C30 questionnaire: Have you had a lack of appetite? |
| Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition | Day 1 | * Proportion of patients with severe malnutrition according to the subjective assessment of the clinician * Proportion of patients with severe malnutrition according to the malnutrition criteria defined by the HAS. |
| Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio | Day 1 | neutrophil/lymphocyte ratio |
Countries
France
Participant flow
Recruitment details
56 oncologists, lung specialists or radiation oncologists treating patients with a malignant lung tumour have recruited patients from outpatient visit, day hospital or in-patient hospitalization in France and Belgium, between the 25th of July and the 31th of October 2016. Patients were recruited in a consecutive manner.
Pre-assignment details
539 patients were recruited. Among them, 5 did not meet the eligibility criteria, 1 withdrew his/her consent, 2 were excluded during the data review because the cancer histology was undefined. The analysis population included 531 patients and among them 312 had skeletal muscle mass assessment.
Participants by arm
| Arm | Count |
|---|---|
| NSCLC Patient Patients,18 years and older, with Non Small Cell Lung Cancer (NSCLC) regardless of the tumor stage and the treatment line | 531 |
| Total | 531 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Protocol Violation | 7 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | NSCLC Patient |
|---|---|
| Age, Continuous | 65.2 year STANDARD_DEVIATION 10 |
| Histology type Adenocarcinoma | 348 Participants |
| Histology type Large cell carcinoma | 18 Participants |
| Histology type Others | 25 Participants |
| Histology type Squamous cell carcinoma | 140 Participants |
| Molecular abnormalities EGFR, ALK, ROS1, BRAF or HER2 | 54 Participants |
| Molecular abnormalities K-RAS | 61 Participants |
| Molecular abnormalities None | 214 Participants |
| Performance Status ECOG (Eastern Cooperative Oncology Group) 0 | 124 Participants |
| Performance Status ECOG (Eastern Cooperative Oncology Group) 1 | 300 Participants |
| Performance Status ECOG (Eastern Cooperative Oncology Group) 2 | 87 Participants |
| Performance Status ECOG (Eastern Cooperative Oncology Group) 3 | 19 Participants |
| Performance Status ECOG (Eastern Cooperative Oncology Group) 4 | 1 Participants |
| Sex: Female, Male Female | 178 Participants |
| Sex: Female, Male Male | 353 Participants |
| Smoking status Current smoker | 97 Participants |
| Smoking status Missing | 11 Participants |
| Smoking status Non smoker | 64 Participants |
| Smoking status Past smoker | 359 Participants |
| Tumor stages Stage I-II | 34 Participants |
| Tumor stages Stage IIIA | 21 Participants |
| Tumor stages Stage IIIB-IV | 440 Participants |
| Tumor stages Unknown stage | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
Primary
Frequency of Cachexia According to Modified Fearon Criteria
Percentage of NSCLC patients with a cachexia according to Fearon criteria modified for the stages of pre-cachexia and refractory cachexia in order to classify all the featured cases without ambiguity. A patient was considered to have cachexia if he/she had: * Weight loss \>5% in the last 6 months prior to inclusion or * BMI \<20 kg/m² and weight loss between 2 and 5% in the 6 months prior to inclusion or * Weight loss \>2% and sarcopenia (as evaluated by the muscle mass index at L3) if available. If data were not available regarding possible sarcopenia, the presence of cachexia was assigned based on the 2 above conditions. In the 3 cases defined above, patient should not have entered the refractory cachexia stage, which was defined as: ECOG performance score of 3 or 4 and a low survival expectancy as defined by Martin et al. (J Clin Oncol 2015) (BMI \<20 kg/m² and weight loss ≥ 6%) or (20 ≤ BMI ≤ 21.9 kg/m² and weight loss ≥ 11%) or (22 kg/m² ≤ BMI and weight loss ≥ 15%).
Time frame: Day1
Population: missing data for 84 patients
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Frequency of Cachexia According to Modified Fearon Criteria | 173 Participants |
Secondary
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia
* Proportion of patients with anorexia according to the subjective assessment of the clinician * Proportion of patients with anorexia according to the Ingesta VAS * Proportion of patients with anorexia according to the AC/S-FAACT module score * Proportion of patients with anorexia according to question 13 of the QLQ-C30 questionnaire: Have you had a lack of appetite?
Time frame: Day 1
Population: NSCLC patients Anorexia according to Investigator: 3 missing data Anorexia according to VAS: 22 missing data Anorexia according to FAACT: 19 missing data Anorexia according to question 13 of QLQ-C30 questionnaire: 33 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia | 109 Participants |
| Cancer Stage IIIA | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia | 166 Participants |
| Cancer Stage IIIB- IV | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia | 273 Participants |
| 3 NSCLC Treatments | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Anorexia | 219 Participants |
Secondary
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia
* Proportion of patients with cachexia according to the subjective assessment of the clinician * Proportion of patients with cachexia according to the Fearon criteria
Time frame: Day 1
Population: NSCLC patients Cachexia according to Investigator: 4 missing data Cachexia according to Fearon criteria: 84 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia | 53 Participants |
| Cancer Stage IIIA | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Cachexia | 173 Participants |
Secondary
Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition
* Proportion of patients with severe malnutrition according to the subjective assessment of the clinician * Proportion of patients with severe malnutrition according to the malnutrition criteria defined by the HAS.
Time frame: Day 1
Population: NSCLC patients Severe malnutrition according to Investigator: 15 missing data Severe malnutrition according to the HAS: 416 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition | 52 Participants |
| Cancer Stage IIIA | Comparison of the Proportion of Patients With Cachexia, Anorexia and Malnutrition According to the Subjective Assessment of the Clinician and the Different Objective Assessment Criteria: Malnutrition | 55 Participants |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose
Blood glucose abnormalities according to the different stages of cachexia at inclusion
Time frame: Day 1
Population: NSCLC patients 329 data missing
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Refractory cachexia | 1 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Cachexia | 21 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Pre-cachexia | 20 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | No cachexia | 14 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Cachexia | 16 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Pre-cachexia | 15 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | No cachexia | 5 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Refractory cachexia | 0 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Pre-cachexia | 12 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | No cachexia | 4 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Refractory cachexia | 0 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Blood Glucose | Cachexia | 10 Participants |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP
CRP level
Time frame: Day 1
Population: NSCLC patients 317 missing data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP | 18 mg/L |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP | 7 mg/L |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP | 21.5 mg/L |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - CRP | 16.5 mg/L |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen
fibrinogen level
Time frame: Day 1
Population: NSCLC patients 387 missing data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen | 4.58 g/L |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen | 4.75 g/L |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Fibrinogen | 4.96 g/L |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio
neutrophil/lymphocyte ratio
Time frame: Day 1
Population: NSCLC patients 112 missing data
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio | 2.54 no unit (ratio) |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio | 2.73 no unit (ratio) |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio | 3.75 no unit (ratio) |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Inflammation Markers - Neutrophil/Lymphocyte Ratio | 7.15 no unit (ratio) |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT
Score of the 12-question AC/S module (Anorexia-Cachexia module) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire assessing anorexia and cachexia: the AC/S module of the FAACT questionnaire consists of 12 questions to assess over the last 7 days quality of life, related to anorexia or cachexia. The score ranges between 0 and 48, the higher the score, the higher the quality of life.
Time frame: Day 1
Population: NSCLC patients 9 missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT | 40.00 score on a scale | Standard Deviation 3.9 |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT | 35.09 score on a scale | Standard Deviation 7.02 |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT | 32.60 score on a scale | Standard Deviation 7.16 |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - AC/S FAACT | 25.75 score on a scale | Standard Deviation 10.05 |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale
Dietary Intake Visual Analog Scale (Dietary intake VAS): The question Could you indicate the amount you currently eat, placing a vertical mark on the line between nothing at all and as usual? . Depending on the location of the patient mark on the scale, a score of between 0 (nothing at all) and 10 (as usual) will be allocated.
Time frame: Day 1
Population: NSCLC patients 12 missing data
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale | 9.57 score on a scale | Standard Deviation 1.07 |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale | 7.68 score on a scale | Standard Deviation 2.64 |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale | 6.51 score on a scale | Standard Deviation 2.89 |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Loss of Appetite - Dietary Intake Visual Analog Scale | 3.13 score on a scale | Standard Deviation 1.16 |
Secondary
Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State
• Nutritional state according to the different stages of cachexia The variables used will be: serum albumin levels, serum pre-albumin levels, BMI and weight.
Time frame: Day 1
Population: NSCLC patients
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | No Cachexia | 0 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Pre-Cachexia | 0 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Cachexia | 29 Participants |
| NSCLC Patients With Cachexia | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Refractory Cachexia | 2 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | No Cachexia | 0 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Refractory Cachexia | 3 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Pre-Cachexia | 0 Participants |
| Cancer Stage IIIA | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Cachexia | 60 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Refractory Cachexia | 2 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Pre-Cachexia | 7 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Cachexia | 21 Participants |
| Cancer Stage IIIB- IV | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | No Cachexia | 5 Participants |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | No Cachexia | 2 Participants |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Pre-Cachexia | 1 Participants |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Refractory Cachexia | 0 Participants |
| 3 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Cachexia | 3 Participants |
| at Least 4 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Refractory Cachexia | 3 Participants |
| at Least 4 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Cachexia | 37 Participants |
| at Least 4 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | Pre-Cachexia | 20 Participants |
| at Least 4 NSCLC Treatments | Description of the Clinical Signs/Symptoms Associated With the Different Stages of Cachexia: Nutritional State | No Cachexia | 8 Participants |
Secondary
Description of the Level of Physical Activity Associated With the Different Stages of Cachexia.
Three levels of physical activity are defined: 1. \- Low * No activity is reported OR * An activity is reported but does not reach moderate or high levels. 2. \- Moderate Corresponds to one of the following 3 criteria: * 3 or more days of intense activity lasting at least 20 min per day OR * 5 or more days of moderate intensity activity and / or walking for at least 30 min per day OR * 5 or more days of activity combining walking, activities of moderate or high intensity, thus achieving at least 600 MET-minutes / week 3. \- High Corresponds to one of the following 2 criteria: * Intense activity at least 3 days a week and at least 1500 MET-minutes / week OR * 7 or more days of activity combining walking, moderate and high intensity activities, achieving at least 3000 MET-minutes / week
Time frame: Day 1
Population: NSCLC patients 69 missing data
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Low | 30 Participants |
| NSCLC Patients With Cachexia | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | High | 38 Participants |
| NSCLC Patients With Cachexia | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Moderate | 34 Participants |
| Cancer Stage IIIA | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Low | 56 Participants |
| Cancer Stage IIIA | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | High | 30 Participants |
| Cancer Stage IIIA | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Moderate | 42 Participants |
| Cancer Stage IIIB- IV | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Moderate | 39 Participants |
| Cancer Stage IIIB- IV | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Low | 78 Participants |
| Cancer Stage IIIB- IV | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | High | 27 Participants |
| 3 NSCLC Treatments | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Low | 4 Participants |
| 3 NSCLC Treatments | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | High | 0 Participants |
| 3 NSCLC Treatments | Description of the Level of Physical Activity Associated With the Different Stages of Cachexia. | Moderate | 0 Participants |
Secondary
Description of the Quality of Life Associated With the Different Stages of Cachexia.
Quality of life has been analysed using scores from the functional scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 items (EORTC QLQ-C30 questionnaire): score ranging from 0 (malfunction) to 100 (healthy level of functioning) for the following parameters : physical, role, cognitive, emotional and social scales
Time frame: Day 1
Population: NSCLC patients Physical scale: 16 missing data Role scale: 17 missing data Cognitive scale: 16 missing data Emotional scale: 16 missing data Social scale: 18 missing data
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| NSCLC Patients With Cachexia | Description of the Quality of Life Associated With the Different Stages of Cachexia. | No Cachexia | 76.6 Scale score | Standard Deviation 20.1 |
| NSCLC Patients With Cachexia | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Pre-Cachexia | 67.0 Scale score | Standard Deviation 21.4 |
| NSCLC Patients With Cachexia | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Cachexia | 62.8 Scale score | Standard Deviation 24.5 |
| NSCLC Patients With Cachexia | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Refractory Cachexia | 13.3 Scale score | Standard Deviation 9.4 |
| Cancer Stage IIIA | Description of the Quality of Life Associated With the Different Stages of Cachexia. | No Cachexia | 77.6 Scale score | Standard Deviation 26.9 |
| Cancer Stage IIIA | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Refractory Cachexia | 0.0 Scale score | Standard Deviation 0 |
| Cancer Stage IIIA | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Pre-Cachexia | 62.6 Scale score | Standard Deviation 32.5 |
| Cancer Stage IIIA | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Cachexia | 56.2 Scale score | Standard Deviation 35.5 |
| Cancer Stage IIIB- IV | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Refractory Cachexia | 83.3 Scale score | Standard Deviation 19.2 |
| Cancer Stage IIIB- IV | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Pre-Cachexia | 79.7 Scale score | Standard Deviation 23.4 |
| Cancer Stage IIIB- IV | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Cachexia | 79.1 Scale score | Standard Deviation 22.3 |
| Cancer Stage IIIB- IV | Description of the Quality of Life Associated With the Different Stages of Cachexia. | No Cachexia | 84.5 Scale score | Standard Deviation 21 |
| 3 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | No Cachexia | 82.0 Scale score | Standard Deviation 18.2 |
| 3 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Pre-Cachexia | 71.5 Scale score | Standard Deviation 25.1 |
| 3 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Refractory Cachexia | 45.8 Scale score | Standard Deviation 35 |
| 3 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Cachexia | 68.1 Scale score | Standard Deviation 24.8 |
| at Least 4 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Refractory Cachexia | 12.5 Scale score | Standard Deviation 8.3 |
| at Least 4 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Cachexia | 67.8 Scale score | Standard Deviation 31.7 |
| at Least 4 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | Pre-Cachexia | 72.0 Scale score | Standard Deviation 28.9 |
| at Least 4 NSCLC Treatments | Description of the Quality of Life Associated With the Different Stages of Cachexia. | No Cachexia | 84.9 Scale score | Standard Deviation 21.3 |
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: 0.1085Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: 0.0482Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Comparison: Statistical analysis compares all cachexia stages.p-value: <0.0001Kruskal-Wallis
Secondary
Frequency of Sarcopenia in the General NSCLC Patients With Cachexia
Percentage of patients with sarcopenia in the general NSCLC patients with cachexia
Time frame: Day 1
Population: Population with no missing data for the 3 interest criteria defining the cachexia
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Frequency of Sarcopenia in the General NSCLC Patients With Cachexia | 74 Participants |
Secondary
Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia
Percentage of patient with sarcopenia and no clinical significant weight loss (sarcopenia and WL\< 2%) in the general NSCLC patients with pre-cachexia:
Time frame: Day 1
Population: Population with no missing data for the 3 interest criteria defining the pre-cachexia
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Frequency of Sarcopenia With no Clinical Significant Weight Loss in the General NSCLC Patients With Pre-cachexia | 59 Participants |
Secondary
Frequency of the Different Stages of Cachexia According to the Number of Treatments Received.
NSCLC patients. 84 patients with missing data
Time frame: Day 1
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | No Cachexia | 6 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Pre-Cachexia | 11 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Cachexia | 24 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | No Cachexia | 18 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Refractory Cachexia | 1 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Pre-Cachexia | 31 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Cachexia | 32 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Refractory Cachexia | 3 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Pre-Cachexia | 42 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Cachexia | 50 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | No Cachexia | 42 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | No Cachexia | 26 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Pre-Cachexia | 22 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Refractory Cachexia | 0 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Cachexia | 31 Participants |
| at Least 4 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Refractory Cachexia | 0 Participants |
| at Least 4 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Cachexia | 36 Participants |
| at Least 4 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | Pre-Cachexia | 44 Participants |
| at Least 4 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Number of Treatments Received. | No Cachexia | 27 Participants |
Secondary
Frequency of the Different Stages of Cachexia According to the Types of Treatments Received.
Stage of cachexia at inclusion according to the type of treatments received (surgery, radiotherapy, chemotherapy, targeted therapies).
Time frame: Day 1
Population: NSCLC patients. 101 missing data
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | No Cachexia | 7 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Pre-Cachexia | 16 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Cachexia | 16 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Pre-Cachexia | 50 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Cachexia | 40 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Refractory Cachexia | 1 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | No Cachexia | 42 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Cachexia | 146 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Pre-Cachexia | 121 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Refractory Cachexia | 4 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | No Cachexia | 107 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Refractory Cachexia | 0 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Pre-Cachexia | 42 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | No Cachexia | 16 Participants |
| 3 NSCLC Treatments | Frequency of the Different Stages of Cachexia According to the Types of Treatments Received. | Cachexia | 21 Participants |
Secondary
Frequency of the Different Stages of Cachexia in the General NSCLC Population
Percentage of the different stages of cachexia at inclusion. The different stages of cachexia used the following classification: * No Cachexia: 1) no weight loss (WL\<2%) or 2) weight gain AND no anorexia AND no sarcopenia * The pre-cachexia stage : 1) 2% ≤ weight loss ≤ 5% AND BMI ≥ 20 and/or 2) anorexia (according to question 13 of the quality of life questionnaire QLQ-C30) and/or 3) weight loss \< 2% AND sarcopenia * Cachexia: 1) Weight loss \> 5% OR 2) weight loss between 2 and 5% AND BMI \< 20 kg/m² OR 3) weight loss \> 2% AND sarcopenia. In all cases, patient should not have entered the refractory cachexia stage * Refractory cachexia: ECOG 3 or 4 AND low survival expectancy \[BMI \< 20kg/m² and weight loss ≥ 6%\] OR \[20 ≤ BMI ≤ 21,9 kg/m² and weight loss ≥ 11%\] OR \[22 kg/m² ≤ BMI and weight loss ≥ 15%\]
Time frame: Day 1
Population: Missing data for 84 patients
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population | No Cachexia | 119 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population | Pre-Cachexia | 151 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population | Cachexia | 173 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population | Refractory Cachexia | 4 Participants |
Secondary
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC.
Percentage of the different stages of cachexia according to the NSCLC histology
Time frame: Day 1
Population: Patients,18 years and older, with Non Small Cell Lung Cancer (NSCLC) Missing data for 84 patients
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | No Cachexia | 35 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Pre-Cachexia | 38 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Cachexia | 43 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Refractory Cachexia | 4 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | No Cachexia | 79 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Cachexia | 115 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Pre-Cachexia | 98 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Pre-Cachexia | 15 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | Cachexia | 15 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Histology Associated With NSCLC. | No Cachexia | 5 Participants |
Secondary
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC.
Percentage of the different stages of cachexia according to the molecular abnormalities associated with NSCLC: * EGRF, ALK, ROS1, BRAF or HER2 * K-RAS * No mutation
Time frame: Day 1
Population: NSCLC patients Overall number of patients analyzed for cachexia stage; 244 missing data.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | No Cachexia | 8 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Pre-Cachexia | 27 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Cachexia | 11 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | No Cachexia | 21 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Cachexia | 24 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Pre-Cachexia | 13 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Refractory Cachexia | 2 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Pre-Cachexia | 54 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | Cachexia | 79 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC. | No Cachexia | 48 Participants |
Comparison: Statistical analysis applies to all rows and columns.p-value: 0.0032likelihood-ratio test
Comparison: Statistical Analysis 2 for Frequency of the Different Stages of Cachexia, excluding the refractory cachexia stage, in the General NSCLC Population According to Molecular Abnormalities Associated With NSCLC.~Statistical analysis applies to all rows and columns.p-value: 0.0008Chi-squared
Secondary
Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC.
Percentage of the different stages of cachexia at inclusion according to the NSCLC stage
Time frame: Day 1
Population: Patients,18 years and older, with Non Small Cell Lung Cancer (NSCLC) Missing data for 81 patients
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | No Cachexia | 9 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Pre-Cachexia | 10 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Cachexia | 11 Participants |
| NSCLC Patients With Cachexia | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Refractory Cachexia | 1 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Refractory Cachexia | 0 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | No Cachexia | 3 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Cachexia | 5 Participants |
| Cancer Stage IIIA | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Pre-Cachexia | 5 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Refractory Cachexia | 3 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Pre-Cachexia | 124 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | Cachexia | 148 Participants |
| Cancer Stage IIIB- IV | Frequency of the Different Stages of Cachexia in the General NSCLC Population According to Stage Associated With NSCLC. | No Cachexia | 95 Participants |
Secondary
Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms
Non-pharmacological treatment of cachexia or associated symptoms: Y/N
Time frame: Day 1
Population: NLSCS patients with a nutritional consultation within 2 months before inclusion~1 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms | 24 Participants |
| Cancer Stage IIIA | Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms | 41 Participants |
| Cancer Stage IIIB- IV | Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms | 77 Participants |
| 3 NSCLC Treatments | Number of Participants Receiving a Non-Pharmacological Treatment for Cachexia or for Associated Symptoms | 3 Participants |
Secondary
Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms
Pharmacological treatment of cachexia or associated symptoms: Yes / No
Time frame: Day 1
Population: NSCLC patients 225 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms | 0 Participants |
| Cancer Stage IIIA | Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms | 0 Participants |
| Cancer Stage IIIB- IV | Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms | 1 Participants |
| 3 NSCLC Treatments | Number of Participants Receiving a Pharmacological Treatment for Cachexia or for Associated Symptoms | 0 Participants |
Secondary
Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments
Treatments with systemic corticosteroids, anti-inflammatory drugs, Omega 3 fatty acids: Yes/No
Time frame: Day 1
Population: NSCLC patients 11 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments | 35 Participants |
| Cancer Stage IIIA | Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments | 60 Participants |
| Cancer Stage IIIB- IV | Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments | 76 Participants |
| 3 NSCLC Treatments | Number of Participants Receiving Systemic Corticosteroids, Anti-inflammatory Drugs, Omega 3 Fatty Acids Treatments | 3 Participants |
Secondary
Number of Participants With Diabetes Treatments
Diabetes treatments : Yes/No
Time frame: Day 1
Population: NSCLC patients 6 missing data
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| NSCLC Patients With Cachexia | Number of Participants With Diabetes Treatments | 9 Participants |
| Cancer Stage IIIA | Number of Participants With Diabetes Treatments | 15 Participants |
| Cancer Stage IIIB- IV | Number of Participants With Diabetes Treatments | 20 Participants |
| 3 NSCLC Treatments | Number of Participants With Diabetes Treatments | 0 Participants |